Home › All Companies › AKTX › Insider Trading

Akari Therapeutics Plc (AKTX) — Insider Trading

AI-Powered SEC Filing Analysis

← All AKTX filings
Latest Insider Trading Filed: 2026-03-16

Key Insights

  • The reporting person, James R. Neal, acquired pre-funded warrants and accompanying warrants to purchase up to 4,946 American Depositary Shares (ADSs) of Akari Therapeutics Plc on December 16, 2025 in a private placement transaction.
  • The reporting person also acquired pre-funded warrants and warrants to purchase up to 6,186 ADSs in exchange for cancellation of an outstanding promissory note held by the reporting person.
  • All of the acquired warrants and pre-funded warrants are subject to shareholder approval and have five-year terms or are exercisable until fully exercised.
Sentiment: Positive Significance: 6/10
View Original Filing →

Want the newest filings?

This analysis covers the filing from 2026-03-16. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.